University Researchers Develop mRNA Vaccine Strategy to Enhance Cancer-Fighting T Cells
Researchers from the University of Houston, MIT, and Harvard have developed a novel mRNA-based strategy that significantly enhances the T-cell response to vaccines. This advancement could lead to more effective cancer vaccines and improved protection against infectious diseases. The new approach involves reprogramming immune cells using mRNA instructions to expand cancer-fighting T cells. The adjuvant, created with mRNA molecules, delivers instructions for immune-related genes IRF8 and NIK, activating key immune pathways. In mouse studies, this mRNA-encoded adjuvant enabled the immune system to eradicate tumors in various cancer models, either alone or with a tumor antigen. The adjuvant also boosted T-cell responses to vaccines against influenza and Covid-19. The research, led by Akash Gupta, was published in Nature Biotechnology and funded by Sanofi, the National Institutes of Health, and other institutions. 
